Molecular Evidence (rationale) for NFAT targeted therapy in iMCD patients:

NFAT is a primary transcription factor for T cell activation. Soluble IL-2 receptor, a marker of T cell activation, is found to be elevated in 20 out of 21 cases of iMCD. (Liu et al)

Case Reports of anti-NFAT therapy for iMCD patients:

There are no existing therapies that target NFAT. 

Clinical Trials targeting NFAT in iMCD patients:

No clinical trials targeting NFAT in iMCD patients have been conducted.